Researchers at the Research Center Pharmaceutical Engineering in Graz, Austria, 3D print pessaries for patients using a novel process and innovative materials.
HEMO2life® oxygen carrier medical device derived from Arenicola marina lugworm facilitating grafts preservation without delayed graft function opens up new opportunities to complex transplants.
Aiming to emulate the quantum characteristics of materials more realistically, researchers have figured out a way to create a lattice of light and atoms that can vibrate – bringing sound to an otherwise silent experiment.
VinFuture Foundation will hold its Online Science Dialogue series' second installment discussing "Renewable energy and new materials for the future" on November 12th, 2021. The Dialogue will see the attendance of world-class scientists, most notably Professor Konstantin (Kostya) Sergeevich Novoselov, a Nobel Prize laureate in Physics. The event is aimed at bringing science and technology closer to the general public with solutions that have high real-world applicability.
The National Kidney Donation Organization (NKDO) has implemented Donor Connect, a living donor mentor program, at three major kidney transplant centers: Hackensack University Medical Center’s Kidney Transplant Program, MedStar Georgetown University Hospital, and Penn Transplant Institute.
VTT Technical Research Centre of Finland, LUT University, Business Finland, and a group of companies have launched a two-year research project aimed at promoting competitiveness among Finnish companies on international markets.
"Innovate in Neurology to fight stroke". Lys Therapeutics, a French biotech company developing innovative drugs to treat patients suffering from neurological diseases including stroke, along with the Blood and Brain @ Caen-Normandie Institute (BB@C), announced today they will host a scientific conference in support of World Stroke Day.
Entasis Therapeutics Holdings Inc. (Nasdaq:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.
The event will feature the participation of John O'Keefe, British-American neuroscientist and psychologist who, in 2014, together with Edvard Moser and May Britt received the Nobel Prize in Medicine. The wonders of the brain and neuroscience at UNAB, Universidad Autónoma de Bucaramanga, Colombia.